Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|September 9, 2009
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromesTamara Intermesoli, Federica Delaini, Sara Acerboni, et al.
Hematology (Amsterdam, Netherlands)|February 14, 2019
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemiaNicola Gökbuget, Hervé Dombret, Sebastian Giebel, et al.
Blood Advances|January 25, 2020
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trialGiacomo Gianfaldoni, Francesco Mannelli, Tamara Intermesoli, et al.
Blood|February 2, 2024
Management of ALL in adults: 2024 ELN recommendations from a European expert panelNicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, et al.
Blood|January 31, 2024
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panelNicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, et al.
Haematologica|May 10, 2007
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemiaOrietta Spinelli, Barbara Peruta, Manuela Tosi, et al.
Haematologica|June 12, 2013
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy programTamara Intermesoli, Alessandro Rambaldi, Giuseppe Rossi, et al.
Leukemia Research|February 12, 2022
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experienceEleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.
Haematologica|September 3, 2016
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaNicola Gökbuget, Hervè Dombret, Jose-Maria Ribera, et al.
Pageof 8